Nicolás Meyer
Hôpital Civil, Strasbourg(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Nonmelanoma Skin Cancer Studies, Cutaneous Melanoma Detection and Management, CAR-T cell therapy research, Melanoma and MAPK Pathways
Most-Cited Works
- → Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma(2015)2,746 cited
- → Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
- → Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial(2016)972 cited
- → Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial(2017)763 cited
- → A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma(2011)515 cited
- → Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients(2017)417 cited
- → Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial(2019)390 cited
- → TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma(2017)359 cited
- → The TNF Paradox in Cancer Progression and Immunotherapy(2019)298 cited
- → Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial(2017)281 cited